Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and reported. The objective of this review was to comprehensively characterize the incidence, presentation, and management of endocrinopathies following ipilimumab therapy in a single center that is highly specialized in immune checkpoint blockade. We carried out a retrospective analysis of endocrine irAEs in melanoma patients receiving ipilimumab therapy in clinical trials between 2007 and 2013. A total of 256 patients were included in this analysis. We reviewed pituitary-, thyroid-, and adrenal-related hormone test results, as well as radiographic studies and the clinical histories of patients, to identify and characterize cases of hypophysitis, hypothyroidism, thyroiditis, and adrenal dysfunction. Following ipilimumab therapy, the overall incidence of hypophysitis was 8% and that of hypothyroidism/thyroiditis 6%. Primary adrenal dysfunction was rare. Therapy with a combination of ipilimumab and nivolumab, an anti-programmed cell death 1 (PDCD1, also called PD1) receptor antibody, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis. Symptomatic relief, in particular, for hypophysitis, was achieved in all patients with hormone replacement, although endogenous hormone secretion rarely recovered. In summary, we observed that CTLA4 blockade alone, and in particular in combination with PD1 blockade, is associated with an increased risk of symptomatic, sometimes severe, hypophysitis as well as thyroid dysfunction. Prompt initiation with hormone replacement reverses symptoms. Evaluation and reporting of endocrine irAEs in clinical trials should be done using standardized diagnostic criteria and terminology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“novel biological drugs inducing hypophysitis such as ipilimumab or other check-point inhibitors (63).”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“the rexinoids (e.g. bexarotene), directly repressing TSHβ expression”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
In the citing paper
“mitotane, which decreases viability of thyrotrope cells”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The higher overall incidence of hypophysitis in the studies (8%) reviewed compared with that in most of the published trials probably reflects our welldefined clinical, biochemical, and radiographic criteria for identifying cases, which is highly inconsistent and ambiguous in published clinical trials (Hodi et al. 201…”
BackgroundResultInfluentialSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Nivolumab, a second antibody-derived immune regulator, blocks the activation of the anti-programmed cell death 1 (PDCD1, also called PD1) receptor (Topalian et al. 2012).”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 2×
“…pituitary hormone secretion. http://erc.endocrinology-journals.org q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0499 Printed in Great Britain There is a clear association betweenCTLA4 and sporadic, autoimmune thyroid disease in humans and mice (Tomer et al. 2001, Ueda et al. 2003).”
BackgroundInfluentialCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“The engagement of CTLA4 by its ligands in the B7 co-stimulatory family suppresses T-cell proliferation, helping restore tissue homeostasis (Egen et al. 2002, Pentcheva-Hoang et al. 2004).”
BackgroundCaturegli, P., Newschaffer, C., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 588
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
CTLA-4 and Not CD28 Is a Susceptibility Gene for Thyroid Autoantibody Production1
Tomer, Y., Greenberg, D. A., Barbesino, G., Concepcion, E., & Davies, T. F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7372 · Cited by 136
Blomhoff, A., Lie, B. A., Myhre, A. G., Kemp, E. H., Weetman, A. P., Akselsen, H. E., Huseby, E. S., & Undlien, D. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031854 · Cited by 117
CTLA-4 and Not CD28 Is a Susceptibility Gene for Thyroid Autoantibody Production
Tomer, Y. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1687 · Cited by 114
Autoimmune Hypophysitis of SJL Mice: Clinical Insights from a New Animal Model
Tzou, S.-C., Lupi, I., Landek, M., Gutenberg, A., Tzou, Y.-M., Kimura, H., Pinna, G., Rose, N. R., & Caturegli, P. (2008) · Endocrinology · doi:10.1210/en.2007-1692 · Cited by 59
Research works printed but not linked: 1
- 2005, 28, 593
Cited by
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Self-citationSchneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
“Pituitary magnetic resonance imaging imaging with gadolinium and selective slides should be considered, searching enlargement or heterogeneity of the gland [40].”
Backgroundon behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Self-citation
Metadata
- Authors
- Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A.
- Affiliations
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Ryder, Mabel
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-04
- Volume
- 21
- Issue
- 2
- Pages
- 371-381
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- PMC
- PMC4573438
- OpenAlex
- W2166107256
- Cited by
- 439
- References
- 14
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 32 · 2021: 44 · 2020: 49 · 2019: 55 · 2018: 53 · 2017: 56 · 2016: 44 · 2015: 25 · 2014: 5
- FWCI
- 20.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- National Cancer Institute (K08CA133183, P50CA172012, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- ipilimumab, immune-related adverse events, CTLA-4 blockade, immune checkpoint inhibitors, advanced melanoma, hypophysitis, hypothyroidism, thyroiditis, adrenal dysfunction, nivolumab, anti-PD-1 therapy, hormone replacement therapy, endocrine toxicity
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Endocrine System Diseases, Humans, Melanoma, Skin Neoplasms, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.